13 Výsledek
TECHNICAL SECTOR
The present invention is related with the field of immunology and human medicine particularly with the generation and selection of a monoclonal antibody (Mab) against the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence that can be used for the diagnosis and
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of molecular biology, immunology and oncology. More particularly, it concerns methods for detecting biomarkers linked to the development of cancer.
2. Description of Related Art
Modern medicine
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of molecular biology, immunology and oncology. More particularly, it concerns methods for detecting biomarkers linked to the development of cancer.
2. Description of Related Art
Modern medicine
FIELD OF THE INVENTION
This invention relates to a simple screening test for colorectal cancer whereby a marker is detected in rectal mucus. More particularly, this marker is detected in the mucus deposited on a support using Schiff's reagent.
BACKGROUND OF THE INVENTION
Colorectal carcinoma is the
BACKGROUND
Cancer treatment regimens are frequently challenged by multi-drug resistance as tumor cells adapt in response to drug treatment. Apoptosis, a type of programmed cell death, involves a series of biochemical events that lead to changes in cell morphology and death. The apoptotic process is
FIELD OF INVENTION
The present invention is related to the field of cancer treatment. In one embodiment, the invention contemplates administering compounds to tumor lesions that induce local expression of .alpha.-gal epitopes within the tumor. In one embodiment, the administration induces regression
DESCRIPTION OF THE INVENTION
1. Technical Field of the Invention
This invention relates to a screening test for large intestinal cancer by detecting the presence of the disaccharide .beta.-D-Gal-(1->>3)-D-GalNAc in large intestinal mucus.
2. Background Art
Cancer of the colon, cecum, and
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to bifunctional glycoproteins having targeting protein and enzyme properties. More particularly, the invention relates to such proteins whose complements of carbohydrate residues have been modified in a manner that enhances
FIELD OF THE INVENTION
The present invention relates to pharmaceuticals that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis both in vitro and in vivo.
Background of the Invention
Cell adhesion is one important property that differentiates multi-cellular organisms from
BACKGROUND OF THE INVENTION
This invention was made with Government support under Grant Nos. CA 30647, CA 42396 and CA 12582 awarded by the National Cancer Institute.
1. Field of the Invention
The present invention relates generally to Epstein-Barr virus-transformed human B-lymphoblastoid cell
This invention relates to a monoclonal antibody and a method for the production thereof. More particularly, it relates to a monoclonal antibody specific for a .alpha..sub.1 -acid glycoprotein or specific for at least one antigenic determinant included in a sugar chain of the following formula which
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Phase Application of PCT/HR2014/000022, filed Jun. 11, 2014, which claims priority to Croatian Patent Application No. P20130568A, filed Jun. 20, 2013, the contents of such applications being incorporated by reference
FIELD OF THE INVENTION
This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also